Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
Arthur B Epstein1, Peter T Van Hoven2, Alan Kaufman3, Warner W Carr41North Shore Contact Lens and Vision Consultants, Roslyn Heights, NY, USA; 2Primary Eyecare Group PC, Brentwood, TN, USA; 3Adult Allergy Clinic and the Division of Allergy and Immunology, Our Lady of Mercy Medical Center, Bronx, NY,...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-04-01
|
| Series: | Clinical Ophthalmology |
| Online Access: | http://www.dovepress.com/management-of-allergic-conjunctivitis-an-evaluation-of-the-perceived-c-a3064 |
| _version_ | 1818894557134192640 |
|---|---|
| author | Arthur B Epstein Peter T Van Hoven Alan Kaufman Warner W Carr |
| author_facet | Arthur B Epstein Peter T Van Hoven Alan Kaufman Warner W Carr |
| author_sort | Arthur B Epstein |
| collection | DOAJ |
| description | Arthur B Epstein1, Peter T Van Hoven2, Alan Kaufman3, Warner W Carr41North Shore Contact Lens and Vision Consultants, Roslyn Heights, NY, USA; 2Primary Eyecare Group PC, Brentwood, TN, USA; 3Adult Allergy Clinic and the Division of Allergy and Immunology, Our Lady of Mercy Medical Center, Bronx, NY, USA; 4Southern California Research, Mission Viejo, CA, USAPurpose: Results from 2 patient-reported outcome studies of allergic conjunctivitis sufferers who used olopatadine 0.2% and azelastine 0.05% are analyzed.Methods: The PACE (Pataday Allergic Conjunctivitis Evaluation) multi-center, prospective, open-label study examined patient perceptions of olopatadine 0.2% once daily (qd) and previous twice daily (bid) allergic conjunctivitis medications via questionnaire in allergic conjunctivitis sufferers who had previously used bid medication and then initiated olopatadine. A second conjunctival antigen challenge (CAC) study evaluated comfort of 4 allergic conjunctivitis medications. Results: Forty-nine patients from the PACE study (N = 125) with prior azelastine use were examined. Significantly more patients rated themselves “very satisfied” with current olopatadine use compared with past azelastine use on drop comfort (p < 0.0001), speed of relief (p = 0.0004), and overall satisfaction (70% vs 16%, p < 0.0001). Significantly more patients reported olopatadine “very effective” against swelling compared with azelastine (47% vs 8%, p = 0.0404). In the CAC study (N = 36), data from olopatadine (n = 8), azelastine (n = 9) and placebo (N = 36) groups were reported. Olopatadine was rated significantly more comfortable than azelastine upon instillation (p = 0.0223), at 30 seconds (p = 0.0479), and at 1 minute after instillation (p = 0.0240).Conclusion: In the reported studies, olopatadine 0.2% qd was more comfortable than azelastine 0.05% and preferred by patients with allergic conjunctivitis by a ratio of 4:1.Keywords: allergic conjunctivitis, azelastine, ocular allergy, olopatadine, patient perceptions |
| first_indexed | 2024-12-19T18:30:23Z |
| format | Article |
| id | doaj.art-f38fcd8874054b8aa7f35084fdc2594b |
| institution | Directory Open Access Journal |
| issn | 1177-5467 1177-5483 |
| language | English |
| last_indexed | 2024-12-19T18:30:23Z |
| publishDate | 2009-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj.art-f38fcd8874054b8aa7f35084fdc2594b2022-12-21T20:10:45ZengDove Medical PressClinical Ophthalmology1177-54671177-54832009-04-012009default329336Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studiesArthur B EpsteinPeter T Van HovenAlan KaufmanWarner W CarrArthur B Epstein1, Peter T Van Hoven2, Alan Kaufman3, Warner W Carr41North Shore Contact Lens and Vision Consultants, Roslyn Heights, NY, USA; 2Primary Eyecare Group PC, Brentwood, TN, USA; 3Adult Allergy Clinic and the Division of Allergy and Immunology, Our Lady of Mercy Medical Center, Bronx, NY, USA; 4Southern California Research, Mission Viejo, CA, USAPurpose: Results from 2 patient-reported outcome studies of allergic conjunctivitis sufferers who used olopatadine 0.2% and azelastine 0.05% are analyzed.Methods: The PACE (Pataday Allergic Conjunctivitis Evaluation) multi-center, prospective, open-label study examined patient perceptions of olopatadine 0.2% once daily (qd) and previous twice daily (bid) allergic conjunctivitis medications via questionnaire in allergic conjunctivitis sufferers who had previously used bid medication and then initiated olopatadine. A second conjunctival antigen challenge (CAC) study evaluated comfort of 4 allergic conjunctivitis medications. Results: Forty-nine patients from the PACE study (N = 125) with prior azelastine use were examined. Significantly more patients rated themselves “very satisfied” with current olopatadine use compared with past azelastine use on drop comfort (p < 0.0001), speed of relief (p = 0.0004), and overall satisfaction (70% vs 16%, p < 0.0001). Significantly more patients reported olopatadine “very effective” against swelling compared with azelastine (47% vs 8%, p = 0.0404). In the CAC study (N = 36), data from olopatadine (n = 8), azelastine (n = 9) and placebo (N = 36) groups were reported. Olopatadine was rated significantly more comfortable than azelastine upon instillation (p = 0.0223), at 30 seconds (p = 0.0479), and at 1 minute after instillation (p = 0.0240).Conclusion: In the reported studies, olopatadine 0.2% qd was more comfortable than azelastine 0.05% and preferred by patients with allergic conjunctivitis by a ratio of 4:1.Keywords: allergic conjunctivitis, azelastine, ocular allergy, olopatadine, patient perceptionshttp://www.dovepress.com/management-of-allergic-conjunctivitis-an-evaluation-of-the-perceived-c-a3064 |
| spellingShingle | Arthur B Epstein Peter T Van Hoven Alan Kaufman Warner W Carr Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies Clinical Ophthalmology |
| title | Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies |
| title_full | Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies |
| title_fullStr | Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies |
| title_full_unstemmed | Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies |
| title_short | Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies |
| title_sort | management of allergic conjunctivitis an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0 2 and azelastine 0 05 from two prospective studies |
| url | http://www.dovepress.com/management-of-allergic-conjunctivitis-an-evaluation-of-the-perceived-c-a3064 |
| work_keys_str_mv | AT arthurbepstein managementofallergicconjunctivitisanevaluationoftheperceivedcomfortandtherapeuticefficacyofolopatadine02andazelastine005fromtwoprospectivestudies AT petertvanhoven managementofallergicconjunctivitisanevaluationoftheperceivedcomfortandtherapeuticefficacyofolopatadine02andazelastine005fromtwoprospectivestudies AT alankaufman managementofallergicconjunctivitisanevaluationoftheperceivedcomfortandtherapeuticefficacyofolopatadine02andazelastine005fromtwoprospectivestudies AT warnerwcarr managementofallergicconjunctivitisanevaluationoftheperceivedcomfortandtherapeuticefficacyofolopatadine02andazelastine005fromtwoprospectivestudies |